Product Description: Zidesamtinib (NVL-520) is a potent, selective, orally active and brain-penetrant inhibitor of diverse ROS1 fusions and resistance mutations, with IC50s of 0.7 and 7.9 nM for wild-type ROS1 and ROS1 G2032R, respectively, and spares TRK inhibition. Zidesamtinib can be used for the research of cancer[1].
Applications: Cancer-Kinase/protease
Formula: C22H22FN7O
References: [1]Drilon A, et, al. NVL-520 is a selective, TRK-sparing, and brain-penetrant inhibitor of ROS1 fusions and secondary resistance mutations. Cancer Discov. 2022 Dec 13;CD-22-0968.
CAS Number: 2739829-00-4
Molecular Weight: 419.45
Compound Purity: 99.55
Research Area: Cancer
Solubility: DMSO : 50 mg/mL (ultrasonic;warming;heat to 65°C)
Target: ROS Kinase